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Abstract
Background: The HIV co-receptors CXCR4 and CCR5 play an important role in HIV infection and replication.
Therefore we hypothesize that long-term non-progressors (LTNP) with viral control have lower expression of CCR5
and CXCR4 on CD4+ cells, specifically on memory T-lymphocytes since they are the primary target cells of HIV.
Methods: In this cross-sectional study, we included five HIV-infected LTNP with viral control (CD4 > 750 cell/μl &
HIV < 50 copies for ≥2 years), thirteen HIV-infected and seven HIV-uninfected individuals at Radboud UMC Nijmegen,
the Netherlands. We determined the CCR5 and CXCR4 expression among CD4+ and CD8+ lymphocyte subsets;
memory (CD45RO+), naïve (CD45RA+) cells and regulatory T-cells (CD4+CD25highFoxP3+). In addition, CCR5Δ32
polymorphism is related with disease progression and was therefore determined using polymerase chain reaction.
Results: The percentage of CCR5-expressing CD4+ cells of LTNP was comparable with healthy controls; whereas
HIV-infected individuals showed more CCR5-expressing cells. This was observed in memory and naïve CD4+ cells, but
not in regulatory T-cells. The mean fluorescence intensity of CCR5-expressing CD4+ cells was similar in all groups. All
groups had comparable percentages of CXCR4-expressing cells. The mean fluorescence intensity of CXCR4-expressing
cells was significantly higher in HIV-infected normally progressors in both memory and naïve CD4+ cells, but not in
CD8+ cells. The CCR5Δ32 polymorphism was not related to group.
Conclusions: We show that HIV affects -directly or indirectly- the expression of CCR5 in CD4+ T-lymphocytes; yet this
effect is not seen in LTNP with viral control. Avoiding upregulation of CCR5 could be an important method via which
LTNP counteracts the effects of HIV and suppresses viral replication. Exploring how LTNP suppress the upregulation of
CCR5 could be an important step for discovering new therapeutics.
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Background
Human immunodeficiency virus (HIV) infects and destroys
CD4+ T-lymphocytes. Resting CD4+ T-lymphocytes are a
reservoir of HIV infection; subsets of these lymphocytes are
differentially affected by HIV and subdividing these cells in
memory and naïve cells can provide better understanding
of their individual roles [1,2]. Memory T-lymphocytes are
preferentially targeted by HIV, whereas increased numbers
of regulatory T-cells are associated with disease progression
[3]. The density of the CD4 surface marker is associated
with both HIV RNA viral load and disease progression [4].
In addition to CD4 receptors HIV requires a co-receptor,
either CCR5 or CXCR4, to invade cells. In general, HIV
isolated from newly infected individuals uses CCR5 and
these “R5 variants” are detectable over the entire course of
the HIV infection [5]. The X4 variants, that utilize CXCR4,
are mostly detectible at a late stage of the disease and in
only up to 50% of all patients [6]. Both co-receptors
are expressed on leukocytes, but to different extents
on different T-cell subsets [7,8]. CXCR4 is predominantly
found on resting, naïve T-lymphocytes, whereas CCR5 is
expressed on mostly memory T-lymphocytes. Therefore
activated CD4+CCR5+ T-lymphocytes are the primary
target and an optimal subset for virus replication [2].
The number of circulating CD4 cells accurately reflects
the extent of immunodeficiency in HIV-infected patients.
Most HIV-infected patients exhibit a gradual decline in
CD4 cells throughout the course of their infection; the rate
of disease progression from asymptomatic HIV infection to
AIDS varies between patients. Some HIV patients are able
to maintain stable CD4 cell counts for an extended time
and remain asymptomatic without ART for years after
infection. These patients have been referred to as long-term
non-progressors (LTNP). Unfortunately, the underlying
mechanisms for the interindividual variability and slow
progression of HIV are poorly understood. Understanding
mechanisms that are associated with slow progression will
help identify new targets for treatment and even prevention
of HIV infection.
The HIV co-receptors CCR5 and CXCR4 could play a
crucial role in the progression of HIV and non-progression
among LTNP. A well-known polymorphism in the CCR5
gene, namely CCR5Δ32 (a 32 base pair deletion in the
CCR5 gene) interrupts the entrance of HIV into cells and
individuals homozygous for this deletion are almost com-
pletely resistant to HIV infection [9-12]. And individuals
who are heterozygous for the CCR5Δ32 have shown slower
progression of HIV [9,13-15]. Also the expression of CCR5
and CXCR4 is, in addition to CD4, extremely important in
the susceptibility of cells to HIV infection [16] and viral
replication [17,18]. Previous studies have shown that
the expression of CCR5 increased with HIV disease pro-
gression, a phenomenon that is reversed by antiretroviral
therapy (ART) [19]; indicating that CCR5 expression is
important in disease progression. Not only the receptors,
but also its ligands (MIP-1α/CCL3, MIP- 1β/CCL4 and
RANTES/CCL5 for CCR5 and SDF-1/CXCL12 for CXCR4)
have the ability to block HIV activity [12]. Unfortunately,
only little information is available on the expression of
CXCR4 and CCR5 on different subsets of T-lymphocytes,
especially in relation to LTNP. Therefore, we have explored
differences in the expression of CCR5 and CXCR4 in differ-
ent subsets of T-lymphocytes in LTNP with viral control.
Methods
Study population
HIV seropositive, ART-naïve subjects above 18 years of
age were included at the HIV-clinic of the Radboud
University Nijmegen Medical Centre, the Netherlands.
LTNP with viral control were defined as those with a
CD4 cell count above 750 cells/μl and a HIV viral
load below 50 copies/ml for at least 2 years [10,20].
HIV-infected subjects that did not fit these criteria were
classified as HIV-infected normal progressors, and HIV
seronegative healthy individuals were used as controls.
Blood samples of LTNP were always examined in parallel
with samples from a healthy control donor and multiple
HIV-infected normal progressors. Blood samples were
used for standard hematologic blood parameters and flow
cytometry.
Ethics
This study was presented to the institutional review board
of Radboud UMC in Nijmegen, the Netherlands. We
received a waiver for blood collection of HIV infected
individuals and approval for blood collection of healthy
controls from the Medical Ethical Committee Nijmegen in
the Netherlands. All participants, including healthy controls,
were informed about giving blood samples for this specific
study and provided written consent. During a routine
appointment, nurses in the clinic collected the blood
samples and provided these to us anonymously. None of
the researchers had access to participants personal
identifying data and all data was analysed anonymously.
Flow cytometry
Cells were phenotypically analysed by five-colour flow
cytometry (Coulter Cytomics FC 500, Beckman Coulter,
Fullerton, CA) using Coulter Epics Expo 32 software. Both
peripheral blood mononuclear cells (PBMC) and whole
blood (after red cell lysis) were used for flow cytometric
analysis. PBMC were isolated by density centrifugation on
Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden).
Red cell lysis of whole blood was performed according to
the manufacturer’s instruction (BD PharmLyse, Becton
Dickinson Biosciences, San Jose, USA). Cells were washed
with phosphate-buffered saline (PBS) with 1% bovine
serum albumin (BSA) before being incubated with
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fluorochrome- conjugated mAbs. After incubation for
20 min at room temperature, cells were washed twice to
remove unbound antibodies and analysed. For cell surface
staining, the following mAbs were used: CD25-PECy7
(BC96), CD127 PECy5 and PECy7 labelled (RDR5) from
eBioscience (San Diego, USA); CD3-ECD (UCHT1) and
CD4-ECD (SFCI12T4D11) from Beckman Coulter
(San Diego, USA); CD4-PECy7 (RPA-T4), CD8-PECy7
(HIT8a), CD45-APC (HI30), CD14-APC (M5E2), CD19-
PECy7 (HIB19), CD45RO-APC (UCHL1), CD45RA-APC
(HI100), CXCR4-PE (12G5), CCR5-FITC (HEK/1/85a)
from Biolegend (San Diego, USA). Appropriate isotype
control mAbs were used for gate settings. Due to limited
amount of filters per sample memory and naïve lympho-
cytes were identified using CD3 and CD4 in combination
with CD45RO or CD45RA respectively. The live gate was
set based on the forward angle light scatter (FSCs)
and the side angle light scatter (SSCs). For intracellular
staining for FoxP3 we used FoxP3-APC antibodies
(PCP101; eBioscience). Before intracellular staining,
cells were fixed and permeabilised using Fix and Perm re-
agent according to the manufacturer’s recommendations
(eBioscience).
DNA isolation and polymerase chain reaction
DNA was isolated from PBMCs by Puregene DNA isolation
kits (Gentra Puregene blood kit, Qiagen, Hilden, Germany)
according to manufacturer’s instruction. Briefly, cells were
lysed overnight at 37°C before adding protein precipitation
solution. DNA was purified using isopropanol, washed
with 70% ethanol, and then diluted in 10 μl of DNA
hydrolysation solution and incubated overnight at 37°C.
Hydrolysation solution without DNA was used as a
negative control. DNA concentrations were measured
using Nanodrop and samples were stored at 4°C until
analysis. To determine the 32 bp deletion in the CCR5
gene (CCR5Δ32) we used polymerase chain reaction
(PCR) with the following primers: forward primer
5′-ATCACTTGGGTGGTGGCTGTGTTTGCGTCTC-3′
and reverse primer 3′-GACGGCGACGAACAGTACCA
GTAGACGATGA-5′, corresponding to bases 505–535
and 667–697 [21]. Genomic DNA from each individual
was amplified in a total volume of 25 uL in a buffer
containing 10 μM of each primer. The cycling conditions
were: denaturation at 94°C for 5 min (1 cycle), followed
94°C for 60 sec and 70°C for 30 sec for 35 cycles. The
CCR5Δ32 polymorphism was detected with electrophor-
esis with 4% agarose gel stained with ethidium bromide.
The normal allele size is 193 bp and the allele size for the
deletion is 161 bp.
Statistical analyses
We selected subsets of cells by first gating on live cells
and subsequently on CD45+ cells. Within these gated cells
we defined the subsets as follows: monocytes: CD14+;
B-cells: CD19+; T-lymphocytes: CD3+. In the CD3+ cells
we gated on either on CD4+ or CD8+ cells. Further, within
these CD4+ or CD8+ cells we identified CD45RA+ (naïve),
CD45RO+ (memory) and CD25highFoxP3+ (regulatory). In
Figure 1A we give an example of how memory cells were
selected. First we selected all CD45+ cells and plotted CD3
and CD4 markers in a scatterplot (left), then we selected
all CD4+ CD3+ cells and plotted CD4 and CD45RO
markers in a second scatterplot (right). In this plot we
identified memory cells as CD45RO+ CD4+ cells. In
Figure 1B we plotted CD25 and CD4 markers and
identified regulatory T cells as being expressing CD25
high, CD4 and FoxP3. For all cell subtypes, expression of
HIV co-receptors CCR5 and CXCR4 was measured as pro-
portion (%) of positive cells, as well as mean fluorescence
intensity (MFI) of positive cells. The Kruskal Wallis and
Mann Whitney analyses were used to compare differences
between groups. The level of significance was set at 10%.
All statistical analysis was performed using the Statistical
Product and Services Solutions package version 18.0 and
GraphPad Prism version 5.0.
Results
We included five HIV-infected LTNP with viral control,
thirteen HIV-infected normal progressors and seven
healthy controls. None of the HIV-infected subjects took
ART at time of blood collection or previously. The charac-
teristics of the subjects are shown in Table 1; as expected
the median CD4 cells were higher and the viral load
was lower in HIV-infected LTNP than in normal pro-
gressors. HIV was diagnosed a median of eight years
(range: 3–14 years) for LTNP and a median of three
and a half years (range: 1–7 years) for other HIV infected
individuals.
Differences in cell type distribution between groups were
most pronounced for CD4+ subtypes (Table 2). As expected,
HIV-infected normal progressors had significantly lower
CD4+ T-cell counts compared to LTNP and healthy
controls (Table 2). This difference was found for all
CD4+ subsets: memory (CD45RO+), naïve (CD45RA+)
and regulatory (CD25highFoxP3+ cells) T-lymphocytes.
Expression of the HIV co-receptor CCR5 on CD4+ T-cells
was similar in LTNP and healthy controls; both groups
showed lower CCR5 expression compared to HIV-infected
normal progressors (Figure 2A). When CD4-cell subsets
were analysed, this difference was observed in memory
and naïve T-lymphocytes (p-values: 0.007 and 0.046
respectively), but not in regulatory T-cells (p = 0.443)
(Figure 2A). CD8+ T-lymphocytes did not show a difference
in CCR5 expression.
The MFI of CCR5-expressing cells in CD4+ T-lymphocytes
was slightly higher in LTNP and HIV-infected individuals
(Figure 2B; not significant). In all CD8+ T-lymphocyte
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subsets the MFI of CCR5-expressing cells was lower in
HIV-infected normal progressors compared to healthy
controls (Figure 2C).
In LTNP, the proportion of CD4+ T-cells that expressed
CXCR4 was similar (Figure 3A). However, the MFI of
CXCR4-expressing cells was significantly higher in
HIV-infected normal progressors than healthy controls
(Figure 3B). In all subsets of CD8+ T-lymphocytes the
MFI of CXCR4-expressing cells was comparable between
all groups. The differences between groups can be
observed by two representative plots for all cell types
for CCR5 (Figure 4) and CXCR4 (Figure 5).
The CCR5Δ32 polymorphism in the CCR5 receptor
may influence the expression of CCR5 [17]. Therefore
we examined whether this polymorphism is more
prevalent among the LTNP in this study. In total
three people were heterozygote for the CCR5Δ32
polymorphism (12%), one of which was LTNP (1/5)
and two were HIV-infected normal progressors (2/12).
No statistical difference was found between the prevalence
of CCR5Δ32 between LTNP and HIV-infected normal
progressors (p = 0.813). In addition, the CCR5Δ32
polymorphism was not (significantly) associated with
the percentage nor the MFI of CCR5-expressing and
CXCR4-expressing cells.
Table 1 Characteristics of ART-naïve HIV-infected individuals




Number 5 13 7
Median age, years 49 39 41
Median CD4 cells, cells/μl 1240 565 n.a.
Median Log (viral load) 1.7 4.3 n.a.
ART: antiretroviral therapy; HIV: human immunodeficiency virus; LTNP:
long-term non-progressors; IQR: interquartile range.
A
B
Figure 1 Examples of how CD3+CD4+CD45RO+ (A) and CD4+CD25highFoxP3+ (B) cells were selected. A) Cells were first gated on CD3+ CD4+
(green), selected cells were then split in CD45RO+ and CD45RO- cells. Within CD45RO+ cells the expression of CCR5 and CXCR4 was determined.
B) Regulatory T-cells were selected by gating on CD4+ and CD25high cells, and only FOXP3+ cells were used for analyses.
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Discussion
In this study we show that HIV infection is -directly or
indirectly- associated with the expression of CCR5, but
not CXCR4, in specific CD4+ T-lymphocyte subsets. This
effect is most notable in HIV-infected normal progressors,
but barely observed in LTNP with viral control.
CCR5 and CXCR4 are crucial for HIV invasion and they
are expressed on various cell types, including hematopoietic
cells and several cells in the central nervous system
[7,12,17,22-27]. The expression of CCR5 can be affected by
HIV and we show, in line with other studies, that
HIV-infected individuals have an increased CCR5 expres-
sion on CD4+ T-lymphocytes [17,28-31]. Longitudinal
studies show that the percentages of CCR5-expressing
CD4+ cells increases slightly over time [17], while
HAART reduces the percentage of CCR5-expressing
cells [28,29,31,32]. This suggests, that indeed HIV increases
the expression of CCR5 on CD4+ T-lymphocytes and that
this effect is reversible. In contrast, we found no association
between HIV and the surface density of CCR5, expressed
by MFI. This also accords with earlier observations,
which showed that surface density of CCR5 is stable
over time [18,33].
Recently, studies suggest that subtle genetic differences
of HIV are associated with non-progression. HIV derived
from long-term non-progressors has shown a reduced
cell entry in vitro [1,34-37]. Also genetic differences in
the host may play a role; the CCR5Δ32 polymorphism
is associated with lower numbers of CCR5-expressing
CD4+ T-cells [17] and slower progression of HIV
[9,13-15]. However, the CCR5Δ32 polymorphism is
unrelated to the elevated expression of CCR5 in HIV-
infected individuals, both in our study and that of
others [15,17,30]. Despite these contradictory results,
meta-analyses of published cohorts associate the
CCR5Δ32 with lower viral loads, decreased risk of pro-
gression to AIDS and lower mortality rate [13,38]. In
addition slow progression could be associated with
pathways including specific cellular proteins, such as
restriction factors, APOBEC3, TRIM5, and Tetherin.
These molecules act at several key steps of the HIV
lifecycle and can avert viral infection or replication in a
cell-specific way. As they control HIV infection, it is
possible that genetic alterations or levels of expression
are related to differences in HIV progression [39].
We demonstrate that in LTNP with viral control the
expression of CCR5 is lower on both memory (CD45RO+)
and naïve (CD45RA+) CD4+ T-lymphocytes, but not on
regulatory T-cells (CD4+CD25highFoxP3+). Only few
studies examined co-receptors expression among specific
HIV-infected patients, such as elite controls and
LTNP, in combination with specific cell subsets [24,40].
Almeida et al. presents the CCR5 expression in dendritic
cells of HIV-infected patients, including long term
Table 2 Cell types and expression of CCR5 and CXCR4 for HIV-infected and uninfected individuals
Cell type Control LTNP HIV p-value
Total white blood cells, n (*106/L) 6043 7060 5846 0.214
CD14+ of CD45+ cells 9.0 8.2 10.1 0.186
CD3+ of CD45+ cells 24.7 29.9 30.7 0.188
CD8 + CD3+ of CD45 + cells 7.2 11.5 19.1 0.003
CCR5+ 50.6 43.1 57.8 0.161
CXCR4+ 92.2 97.4 95.1 0.590
CD4 + CD3+ of CD45 + cells 14.94 16.62 8.99 0.018
CCR5+ 22.5 16.9 30.0 0.014
CXCR4+ 70.2 83.7 71.9 0.185
CD45RO+ of CD3 + CD4+ cells 49.6 45.6 52.6 0.360
CCR5+ 40.1 30.5 44.4 0.065
CXCR4+ 45.8 70.6 57.7 0.191
CD45RA+ of CD3 + CD4+ cells 45.4 52.6 44.5 0.396
CCR5+ 6.4 8.5 18.6 0.018
CXCR4+ 91.6 94.6 90.3 0.595
CD25highFoxP3+ of CD3 + CD4 + cells 6.5 4.8 5.4 0.091
CCR5+ 49.1 41.9 49.4 0.790
CXCR4+ 97.9 98.2 95.6 0.712
Data are given as percentage unless stated otherwise.
Groups were compared with Kruskal-Wallis analyses.
HIV: human immunodeficiency virus; LTNP: long-term non-progressors; Control: HIV uninfected healthy controls.
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non-progressors. They found lower expression of
CCR5 in all HIV-infected patients [40]. Other studies
showed lower expression of CCR5 CD4+ T lymphocytes
in HIV controllers [24,33]. Since CCR5 expression regu-
lates whether HIV can infect target cells [41] and
CCR5 down-regulation may contribute to the low levels
of infection in LTNP.
Several studies analysed the association between the
expression of CCR5 and disease progression, such as
time to AIDS, CD4 cell decline or serum viral load
levels. In both humans and animals, higher amounts of
circulating CD4+CCR5+ T-lymphocytes are associated
with faster disease progression, higher viral loads and
lower CD4 cell counts [17,18,30,33,42,43]. Our findings
further support an association between CCR5 expression
and HIV progression. In addition, Yang et al. show that in
mangabeys infected with SIV (simian immunodeficiency
virus) the CCR5 expression is significantly lower on all
subsets of cells in slow progressors compared to fast
progressors; which supports our findings [43]. The down-
regulation of CCR5 in LTNP can be influenced by higher
levels of chemokines, which activates receptor internalisa-
tion and thereby reduces CCR5 expression [12,44]. Also
the amount of regulatory T cells are associated with disease




Figure 2 The expression of CCR5 on various subsets of T-
lymphocytes. The percentage (A) and mean fluorescence intensity
(MFI) (B) of CCR5 on several subsets of CD4+ T-lymphocytes and the
MFI of CCR5 (C) on CD8+ T-lymphocytes for healthy controls, long-term
non-progressors (LTNP) and HIV-infected normal progressors. Subsets of
are defines as: memory T-cells: CD3+CD4+CD45RO+ cells; naive T-cells:
CD3+CD4+CD45RA+ cells; regulatory T-cells: CD4+CD25highFoxP3+ cells.
P-values: * < 0.100; ** <0.050; *** <0.001.
A
B
Figure 3 The expression of CXCR4 on various subsets of
T-lymphocytes. The percentage (A) and mean fluorescence intensity
(B) of CXCR4 on several subsets of CD4+ T-lymphocytes for healthy
controls, long-term non-progressors (LTNP) and HIV-infected normal
progressors. Subsets of are defines as: memory T-cells: CD3+
CD4+CD45RO+ cells; naïve T-cells: CD3+ CD4+ CD45RA+ cells; regulatory
T-cells: CD4+ CD25highFoxP3+ cells. P-values: * < 0.100; ** <0.050;
*** <0.001.
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regulatory T cells was higher in HIV normal progressors
than in LRNP with viral control [13].
In our study, the amount of CXCR4-expressing
cells was comparable between groups, but the MFI of
CXCR4-expressing CD4+ T-lymphocytes was significantly
increased in HIV-infected individuals. Literature on the
expression of CXCR4 is inconclusive; some studies
revealed no differences [29,42], whereas others observed
reduced CXCR4 expression on CD4+ cells [17,28,30,31],
CD8+ cells [28,30,31], CD14+ cells [30] and natural killer
cells [32]. CXCR4 is of more importance during later
stages of infection [42] and therefore CXCR4 is probably
less important in LTNP. In addition, all HIV-infected
subjects in our study were asymptomatic and therefore
the expression of CXCR4 might be affected by HIV at a
later stage. Our study shows that LTNP with viral control
tend to have a slightly higher number of CXCR4 expressing
cells, albeit not significant, and also previous studies
showed that there is a correlation between disease
stage and CXCR4 expression of CD4+ T-lymphocytes; with
healthier patients expressing more CXCR4 [30].
Conclusion
In conclusion, the expression of CCR5 on CD4+ T-
lymphocytes could be important in LTNP to counteract
the effects of HIV and suppress viral replication. However,
Figure 4 Representative plots of the expression of CCR5 on various cell types for different groups. Per group, namely healthy controls,
long-term non-progressors (LTNP) and HIV-infected normal progressors, we show histograms from two representative subjects for the expression
of CCR5.
Figure 5 Representative plots of the expression of CXCR4 on various cell types for different groups. Per group, namely healthy controls,
long-term non-progressors (LTNP) and HIV-infected normal progressors, we show histograms from two representative subjects for the expression
of CXCR4.
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since this is a cross-sectional study the decreased expres-
sion of CCR5 could also be a consequence of the sup-
pressed viral load in LTNP. Exploring whether LTNP
suppress the upregulation of CCR5 could be an important
step for discovering new therapeutics. Currently, CCR5
specific blockers, such as Maraviroc, are already used
effectively in HIV treatment regimes, showing the
importance of CCR5 in HIV suppression.
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